Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMURF2 | Q9HAU4 | 1/20 | 0.36 |
| ▸ | SMURF1 | Q9HCE7 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19064399 | 0.77 | NPC1 (0.40) | — | |
| SCHEMBL19064398 | 0.77 | NPC1 (0.40) | — | |
| SCHEMBL16571467 | 0.74 | GRIA1 (0.42) | SMURF2SMURF1HCAR2GRIA1GRIA3 | |
| SCHEMBL19079160 | 0.73 | SMYD3 (0.53) | — | |
| SCHEMBL26103324 | 0.71 | GRIA1 (0.40) | SMURF2SMURF1HCAR2GRIA1GRIA3 | |
| SCHEMBL26469283 | 0.71 | SMURF2 (0.35) | SMURF2SMURF1HCAR2GRIA1GRIA3 | |
| SCHEMBL21998689 | 0.70 | SCD (0.30) | — | |
| SCHEMBL22609288 | 0.68 | GRIA1 (0.46) | SMURF2SMURF1HCAR2GRIA1GRIA3 | |
| SCHEMBL19079591 | 0.68 | SMN1; SMN2 (0.42) | — | |
| SCHEMBL1225982 | 0.67 | S1PR3 (0.37) | SMURF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200148650-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS | Epizyme, Inc. | 2020-05-14 | — | — | US | disclosed |
| US-20200148650-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS | Epizyme, Inc. | 2020-05-14 | — | — | US | disclosed |
| US-10428029-B2 | Isoxazole carboxamide compounds | Epizyme, Inc. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10428029-B2 | Isoxazole carboxamide compounds | Epizyme, Inc. (US) | 2019-10-01 | — | — | US | disclosed |
| EP-3193603-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS | Epizyme, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20170190676-A1 | Isoxazole Carboxamide Compounds | Epizyme, Inc. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170190676-A1 | Isoxazole Carboxamide Compounds | Epizyme, Inc. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170190676-A1 | Isoxazole Carboxamide Compounds | Epizyme, Inc. (US) | 2017-07-06 | — | — | US | disclosed |
| WO-2016040498-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS | Epizyme, Inc. (US) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428029-B2 | Isoxazole carboxamide compounds | SMYD3, SMYD2, SNRPD3 | SMURF2 15/4885SMURF1 47/4885HCAR2 1200/4885 |
| US-20170190676-A1 | Isoxazole Carboxamide Compounds | SMYD3, SMYD2, SNRPD3 | SMURF2 15/4885SMURF1 47/4885HCAR2 1200/4885 |
| US-20200148650-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS | SMYD3, SMYD2, SNRPD3 | SMURF2 20/4885SMURF1 40/4885HCAR2 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.